HSKA Heska Corporation featured news, full reports, and detailed charts
Heska Corporation (HSKA) Wrap Up:
We develop, manufacture, market, sell and support veterinary products. Our core focus is on the canine and feline companion animal health markets where we strive to provide high value products and advance the state of veterinary medicine. 1 -------------------------------------------------------------------------------- Our business is comprised of two reportable segments, Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment (“CCA”) includes diagnostic instruments and supplies as well as single use diagnostic and other tests, vaccines and pharmaceuticals, primarily for canine and feline use. These products are sold directly by us as well as through independent third-party distributors and other distribution relationships. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f03%2f0001104659-08-014804.html#FIS_BUSINESS"Heska Corp. (HSKA*(D):NASDAQ)
Snapshot of Heska Corp. (HSKA)
|
OPEN
$0.40
|
PREVIOUS CLOSE
$0.40
|
|
|
DAY HIGH
$0.42
|
DAY LOW
$0.38
|
|
|
52 WEEK HIGH
04/29/09 - $0.59
|
52 WEEK LOW
03/9/09 - $0.17
|
|
|
MARKET CAP
20.8M
|
AVERAGE VOLUME 3 mo
30.3K
|
|
|
DILUTED EPS TTM
$-0.0018
|
SHARES OUTSTANDING
52.1M
|
|
|
HSKA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
HSKA Top Compensated Officers
Executives, Board Directors
Key developments for Heska Corp. (HSKA)
Heska Corp., Q3 2009 Earnings Call, Oct 27 2009
Heska Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2009. For the second quarter, the company reported net income was $666,000 or $0.01 per diluted share on total net revenue of $22,615,000 against net income of $579,000 or $0.01 per diluted share on total net revenue of $18,629,000 for the same period a year ago. Operating income was $1,386,000 against $1,010,000 for the same period a year ago. Income before income taxes was $1,205,000 against $969,000 for the same period a year ago. For the six months, the company reported net income was $440,000 or $0.01 per diluted share on total net revenue of $44,533,000 against net income of $1,039,000 or $0.02 per diluted share on total net revenue of $38,770,000 for the same period a year ago. Operating income was $1,163,000 against $2,027,000 for the same period a year ago. Income before income taxes was $816,000 against $1,821,000 for the same period a year ago.
Heska Corp., Q2 2009 Earnings Call, Aug 10 2009
HSKA Competitors
| Company | Last | Change |
| ABAXIS Inc | $22.56 USD | -0.02 |
| Corgenix Medical Corp | $0.11 USD | +0.001 |
| Hemagen Diagnostics Inc | $0.10 USD | 0.00 |
| Synbiotics Corp | $0.09 USD | 0.00 |
| Trinity Biotech PLC | $4.07 USD | -0.12 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | HSKA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.3x |
|
| Price/Book | 0.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.1x |
|
|
HSKA |
||
HSKA transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||